Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD7UCAR
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital, Zhejiang University School of Medicine
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD7UCAR is an investigational universal chimeric antigen receptor T-cell (CAR-T) therapy designed to treat CD7-positive malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. Developed using healthy donor T cells, the therapy employs CRISPR/Cas9 gene editing to disrupt the T-cell receptor alpha constant (TRAC) locus, thereby reducing the risk of graft-versus-host disease (GvHD), and the CD7 locus to prevent fratricide among the CAR-T cells. The CAR construct features a second-generation design with a single-chain variable fragment (scFv) derived from the HIT7 monoclonal antibody clone. Preclinical and early clinical data indicate that CD7UCAR can effectively target and eliminate CD7+ tumor cells while maintaining a favorable safety profile through the avoidance of GvHD.
- Other names
- CD7-targeted universal CAR-T cellsCD-7-targeted universal CAR-T cellsCD 7-targeted universal CAR-T cellsanti-CD7 UCAR-Tanti-CD-7 UCAR-Tanti-CD 7 UCAR-T
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on CD7UCAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD7UCAR.